prognostic marker for targeted therapy.pptx
•Download as PPTX, PDF•
0 likes•6 views
This document discusses prognostic markers and their use in targeted cancer therapy. It defines prognostic markers as biological factors that can predict a patient's response to treatment. There are two main types - clinical markers like age and health status, and biological markers that can be measured in blood or tumor tissue, like gene or protein expression. Prognostic markers are used to select patients most likely to benefit from a targeted therapy, monitor treatment response, and predict cancer recurrence or progression. Examples given are BRAF and EGFR mutation status, and HER2 overexpression.
Report
Share
Report
Share
Recommended
cancer.pdf
This document reviews different types of cancer treatments and analyzes the tumor microenvironment and its role in cancer progression and treatment effectiveness. It discusses how the tumor microenvironment, consisting of non-cancerous cells like fibroblasts and immune cells, interacts with tumor cells and affects their behavior and response to therapy. Monitoring changes in the tumor microenvironment using molecular and cellular profiles can help identify new targets for cancer prevention and treatment. The document then provides an overview of common cancer treatment methods like surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, and targeted therapy, and discusses how the tumor microenvironment contributes to tumor heterogeneity and drug resistance.
The Dawn of Personalized Healthcare A Deep Dive into Genomic Medicine Centers...
Genomic Medicine Centers (GMCs) are revolutionizing healthcare by integrating an individual's genetic makeup into their medical care. These specialized facilities offer genetic testing, counseling, and personalized treatment plans based on a patient's unique DNA.
GMCs function as hubs for clinical care, research, and education. They provide patients with access to advanced genetic testing, helping diagnose conditions, assess disease risks, and inform treatment decisions. GMCs also play a crucial role in advancing research by collecting and analyzing patient data to unlock the secrets of how genes influence health and disease. Additionally, they educate healthcare professionals and the public about genomics and its applications in medicine.
The impact of GMCs is far-reaching. They empower patients with knowledge about their own health, pave the way for personalized medicine with targeted therapies, and contribute to the development of new diagnostic tools and drugs. However, challenges remain, including ethical considerations around privacy and discrimination, ensuring equitable access for all, and navigating the complexities of interpreting genetic data.
Looking ahead, GMCs are poised to shape the future of healthcare. As technology advances, we can expect more comprehensive genetic testing, seamless integration with electronic health records, and the development of even more precise therapies based on individual genetic profiles. Ultimately, GMCs hold immense potential for improving patient care, promoting preventative strategies, and creating a healthier future for all.
CANCER BIOMARKER.pptx
Cancer biomarkers are measurable indicators of biological states or conditions that can help diagnose, prognosticate, and predict responses to treatment. Biomarkers can include proteins, gene mutations, extra or missing genes, and other molecules secreted by tumors or representing body responses to cancer. Some commonly used cancer biomarkers measure levels of proteins like HER2, PSA, CA125, and carcinoembryonic antigen to diagnose specific cancer types, determine prognosis, monitor therapy effectiveness, and detect recurrence of cancers like breast, prostate, ovarian, and colon cancer. Biomarkers play an important role in developing and applying new cancer therapies.
Biomarkers in clinical trial
This document discusses biomarkers used in clinical trials. It defines biomarkers as biological measures of biological states that can indicate normal or pathogenic processes. Biomarkers help guide drug development from discovery through clinical trials by reducing attrition. The document outlines biomarker discovery platforms including genomics, proteomics, and imaging. It describes the phases of biomarker evaluation and validation. Biomarkers in clinical trials can be safety, efficacy, surrogate endpoints, predictive, pharmacodynamic, or prognostic. The document provides examples of biomarkers for different diseases and drug indications.
Precision Medicine in Action: Case Studies and Success Stories
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Precision Medicine in Rare Diseases: Navigating Uncharted Territory
Rare diseases, by definition, affect a small number of individuals, making them a challenging area for medical research and treatment. Precision medicine, with its focus on individualized approaches tailored to a patient's unique characteristics, is increasingly becoming a beacon of hope in the realm of rare diseases. This article explores the innovative landscape of precision medicine in addressing the complexities of rare diseases and the unique challenges that come with navigating this uncharted territory.
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Clinical trials in oncology are vital for the advancement of cancer treatments and
care. The US is at the forefront of these clinical trials, with many different study
designs being used to assess the efficacy and safety of new treatments. This article
will explore the current state of oncology clinical trial services in the US, as well as
discuss different types of study designs that are commonly used. It will provide
insight into how these trials are conducted, what data is collected, and how this
information can be used to improve patient care.
The United States Food and Drug Administration (FDA) has released
several guidance documents over the years through the Oncology Center
of Excellence to support the development of oncologic treatments and
diagnoses. Furthermore, information on the clinical trials for the treatment
of different types of cancer or specific interventions can be found on the
National Cancer Institute (NCI) website and Clinical Trials. Currently,
ClinicalTrials.gov, a website maintained by the National Library of
Medicine (NLM) and the National Institutes of Health (NIH) contains
listings of publicly and privately sponsored trials and includes information
on 91,937 studies related to cancer indicating the high volume of
research being conducted in this field.According to the World Health Organization (WHO), cancer is the leading
cause of death worldwide, with a death rate of one in six in 2020 (1).
Aside from the high mortality rate and morbidity associated with cancer, it
also negatively impacts the quality of life and poses a significant financial
burden on patients and payers making it imperative to develop effective
treatments for the disease. According to Global Cancer Observatory
(GLOBACAN), the United States accounted for 13.3% of all estimated
new cases of cancer in 2020 (2). In 2020, the single leading type of
cancer in the United States was breast cancer (11.1%) followed by lung
cancer (10%), prostrate (9,2%), colorectum (6.8%), and melanoma of the
skin (4.2%). Despite the significant prevalence of cancer and numerous
clinical trials conducted for oncology treatments, data have shown an
almost 95% attrition rate for anticancer drugs from Phase I trials until
marketing authorization. Various factors such as inaccurate preclinical
models, lack of suitable biomarkers in clinical trials, and a disconnect
between industry, academia, and regulators are responsible for the high
attrition rate (3). Therefore, it is vital to develop suitable study designs
and protocols for candidate molecules such that they obtain regulatory
approval and can be marketed. In addition to these challenges, the
development of anti-cancer agents comes at a monumental cost of an
estimated $2.8 billion. Several factors such as the choice of relevant
endpoints, the choice of appropriate biomarkers that are guided by tumor
biology, and careful patient selection are expected to improve the overall
fate of oncologic agents in the clinical trial phase
Personalized Medicines - Enhancers of Life's Quality and Their Future
This lecture is presented by our volunteer Bushra Umer, she is from Karachi, Pakistan, and she is covering "Personalized Medicines - Enhancers of Life's Quality and Their Future ".
For video: https://www.youtube.com/watch?v=BSrgJaBYuxg
Recommended
cancer.pdf
This document reviews different types of cancer treatments and analyzes the tumor microenvironment and its role in cancer progression and treatment effectiveness. It discusses how the tumor microenvironment, consisting of non-cancerous cells like fibroblasts and immune cells, interacts with tumor cells and affects their behavior and response to therapy. Monitoring changes in the tumor microenvironment using molecular and cellular profiles can help identify new targets for cancer prevention and treatment. The document then provides an overview of common cancer treatment methods like surgery, chemotherapy, radiation therapy, immunotherapy, hormone therapy, and targeted therapy, and discusses how the tumor microenvironment contributes to tumor heterogeneity and drug resistance.
The Dawn of Personalized Healthcare A Deep Dive into Genomic Medicine Centers...
Genomic Medicine Centers (GMCs) are revolutionizing healthcare by integrating an individual's genetic makeup into their medical care. These specialized facilities offer genetic testing, counseling, and personalized treatment plans based on a patient's unique DNA.
GMCs function as hubs for clinical care, research, and education. They provide patients with access to advanced genetic testing, helping diagnose conditions, assess disease risks, and inform treatment decisions. GMCs also play a crucial role in advancing research by collecting and analyzing patient data to unlock the secrets of how genes influence health and disease. Additionally, they educate healthcare professionals and the public about genomics and its applications in medicine.
The impact of GMCs is far-reaching. They empower patients with knowledge about their own health, pave the way for personalized medicine with targeted therapies, and contribute to the development of new diagnostic tools and drugs. However, challenges remain, including ethical considerations around privacy and discrimination, ensuring equitable access for all, and navigating the complexities of interpreting genetic data.
Looking ahead, GMCs are poised to shape the future of healthcare. As technology advances, we can expect more comprehensive genetic testing, seamless integration with electronic health records, and the development of even more precise therapies based on individual genetic profiles. Ultimately, GMCs hold immense potential for improving patient care, promoting preventative strategies, and creating a healthier future for all.
CANCER BIOMARKER.pptx
Cancer biomarkers are measurable indicators of biological states or conditions that can help diagnose, prognosticate, and predict responses to treatment. Biomarkers can include proteins, gene mutations, extra or missing genes, and other molecules secreted by tumors or representing body responses to cancer. Some commonly used cancer biomarkers measure levels of proteins like HER2, PSA, CA125, and carcinoembryonic antigen to diagnose specific cancer types, determine prognosis, monitor therapy effectiveness, and detect recurrence of cancers like breast, prostate, ovarian, and colon cancer. Biomarkers play an important role in developing and applying new cancer therapies.
Biomarkers in clinical trial
This document discusses biomarkers used in clinical trials. It defines biomarkers as biological measures of biological states that can indicate normal or pathogenic processes. Biomarkers help guide drug development from discovery through clinical trials by reducing attrition. The document outlines biomarker discovery platforms including genomics, proteomics, and imaging. It describes the phases of biomarker evaluation and validation. Biomarkers in clinical trials can be safety, efficacy, surrogate endpoints, predictive, pharmacodynamic, or prognostic. The document provides examples of biomarkers for different diseases and drug indications.
Precision Medicine in Action: Case Studies and Success Stories
Precision medicine, an innovative approach tailoring medical treatment to individual characteristics, holds great promise for improved patient outcomes. In this paradigm, pharmacovigilance plays a crucial role in monitoring and ensuring the safety of personalized treatments. The integration of big data and artificial intelligence (AI) into pharmacovigilance practices becomes paramount for handling the complexities of individualized therapies and identifying potential safety concerns. This article explores the synergies between big data, AI, and pharmacovigilance in the context of precision medicine.
Precision Medicine in Rare Diseases: Navigating Uncharted Territory
Rare diseases, by definition, affect a small number of individuals, making them a challenging area for medical research and treatment. Precision medicine, with its focus on individualized approaches tailored to a patient's unique characteristics, is increasingly becoming a beacon of hope in the realm of rare diseases. This article explores the innovative landscape of precision medicine in addressing the complexities of rare diseases and the unique challenges that come with navigating this uncharted territory.
Cancer Clinical Trials_ USA Scenario and Study Designs.pdf
Clinical trials in oncology are vital for the advancement of cancer treatments and
care. The US is at the forefront of these clinical trials, with many different study
designs being used to assess the efficacy and safety of new treatments. This article
will explore the current state of oncology clinical trial services in the US, as well as
discuss different types of study designs that are commonly used. It will provide
insight into how these trials are conducted, what data is collected, and how this
information can be used to improve patient care.
The United States Food and Drug Administration (FDA) has released
several guidance documents over the years through the Oncology Center
of Excellence to support the development of oncologic treatments and
diagnoses. Furthermore, information on the clinical trials for the treatment
of different types of cancer or specific interventions can be found on the
National Cancer Institute (NCI) website and Clinical Trials. Currently,
ClinicalTrials.gov, a website maintained by the National Library of
Medicine (NLM) and the National Institutes of Health (NIH) contains
listings of publicly and privately sponsored trials and includes information
on 91,937 studies related to cancer indicating the high volume of
research being conducted in this field.According to the World Health Organization (WHO), cancer is the leading
cause of death worldwide, with a death rate of one in six in 2020 (1).
Aside from the high mortality rate and morbidity associated with cancer, it
also negatively impacts the quality of life and poses a significant financial
burden on patients and payers making it imperative to develop effective
treatments for the disease. According to Global Cancer Observatory
(GLOBACAN), the United States accounted for 13.3% of all estimated
new cases of cancer in 2020 (2). In 2020, the single leading type of
cancer in the United States was breast cancer (11.1%) followed by lung
cancer (10%), prostrate (9,2%), colorectum (6.8%), and melanoma of the
skin (4.2%). Despite the significant prevalence of cancer and numerous
clinical trials conducted for oncology treatments, data have shown an
almost 95% attrition rate for anticancer drugs from Phase I trials until
marketing authorization. Various factors such as inaccurate preclinical
models, lack of suitable biomarkers in clinical trials, and a disconnect
between industry, academia, and regulators are responsible for the high
attrition rate (3). Therefore, it is vital to develop suitable study designs
and protocols for candidate molecules such that they obtain regulatory
approval and can be marketed. In addition to these challenges, the
development of anti-cancer agents comes at a monumental cost of an
estimated $2.8 billion. Several factors such as the choice of relevant
endpoints, the choice of appropriate biomarkers that are guided by tumor
biology, and careful patient selection are expected to improve the overall
fate of oncologic agents in the clinical trial phase
Personalized Medicines - Enhancers of Life's Quality and Their Future
This lecture is presented by our volunteer Bushra Umer, she is from Karachi, Pakistan, and she is covering "Personalized Medicines - Enhancers of Life's Quality and Their Future ".
For video: https://www.youtube.com/watch?v=BSrgJaBYuxg
Advances in Biomarkers and Personalized Medicine
Personalized medicine, also known as precision medicine, is an innovative approach to healthcare that takes into account individual variability in genes, environment, and lifestyle for each person. The goal of personalized medicine is to tailor medical decisions and treatments to the specific characteristics of each patient, maximizing therapeutic benefits while minimizing adverse effects. Biomarkers play a crucial role in achieving this personalized approach. Heres the background and significance of biomarkers in personalized medicine Biomarkers are measurable indicators that can be used to evaluate physiological, pathological, or pharmacological responses to disease or treatment. These can be genetic, molecular, biochemical, or imaging based markers that provide information about a patients health status, disease progression, or treatment response. The emergence of sophisticated biotechnological tools, such as genomics, proteomics, metabolomics, and imaging technologies, has revolutionized the field of medicine. These advancements enable the identification and analysis of biomarkers with greater precision and efficiency. K. Pavani | Jakkula Malavikabindu | Dayyala Naveen "Advances in Biomarkers and Personalized Medicine" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59709.pdf Paper Url:https://www.ijtsrd.com/medicine/other/59709/advances-in-biomarkers-and-personalized-medicine/k-pavani
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...The Lifesciences Magazine
Personalized medicine is a paradigm-shifting strategy that aims to give customized therapies based on individual features, genetic makeup, and distinct illness profiles in an era characterized by revolutionary developments in healthcare. DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
This document provides an overview of personalized medicines and various approaches related to personalized drug delivery. It discusses several key points:
1) Personalized medicine aims to integrate a patient's genetic information to select the most appropriate preventative measures or therapies tailored to that individual.
2) New technologies like custom drug delivery systems, 3D printing, and telepharmacy can help develop personalized treatments by optimizing drug efficacy and minimizing side effects.
3) Pharmacogenomics plays an important role in personalized medicine by using genetic data to inform drug development and identify responders, non-responders, and optimal dosages for individuals.
All About Oncology --- Plunes HealthCare
Oncologists work on identifying and minimizing risk factors associated with cancer. This can involve lifestyle changes, vaccinations (such as the HPV vaccine to prevent cervical cancer), and genetic counselling for individuals with a family history of certain cancers.
Precision Medicine in Oncology
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
med genetics
Medical genetics bridges medicine and biology by focusing on how genes influence health and disease. It has several key areas including clinical genetics, genetic counseling, cytogenetics, molecular genetics, and biochemical genetics. These areas involve diagnosing and managing genetic disorders, providing counseling and support to families, analyzing chromosomes, studying genes and mutations, and researching metabolic processes. Recent advances include gene therapy, personalized medicine, and genomics research, which aim to cure diseases, tailor treatments, and enhance understanding of gene-environment interactions, demonstrating medical genetics' potential to transform healthcare.
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptx
The document discusses personalized medicines and customized drug delivery systems. It defines personalized medicine as using genetic profiling and other individual patient characteristics to guide medical treatment. Customized drug delivery systems aim to optimize drug therapy for each patient by controlling dosage and delivery through technologies like bioelectronic medicines, 3D printing of pharmaceuticals, and telepharmacy.
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...PVI, PeerView Institute for Medical Education
Chair and Presenter, Sumanta Kumar Pal, MD, FASCO, Pedro C. Barata, MD, MSc, Toni K. Choueiri, MD, and Cristina Suarez, MD, PhD, prepared useful Practice Aids pertaining to renal cell carcinoma for this CME/MOC/NCPD/AAPA activity titled “Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3yGnLnD. CME/MOC/NCPD/AAPA credit will be available until July 2, 2024.PERSONALIZED MEDICINE and customised drug delivery L-1.pptx
1. Personalized medicine aims to provide tailored treatment based on an individual's unique attributes by using diagnostic tools to identify biological markers, often genetic, to help assess which medical treatments will be most effective.
2. Pharmacogenomics plays a key role by studying how genetic variations affect individual responses to drugs to optimize efficacy and minimize adverse reactions. This allows for more targeted therapies and precise dosing.
3. The Human Genome Project mapped the entire human genetic code, opening up possibilities for diagnosing and treating diseases based on a person's genetic profile. Now, molecular testing guides treatment decisions and replaces some invasive procedures.
Personalized medicine, Pharmacogenomics, customized drug delivery systems,3d ...
Personalized medicine aims to improve health care by integrating information about a person's genes, proteins, and other factors to tailor medical treatment. This includes using genetic or other tests to select treatments, determine dosage, and predict drug responses. Pharmacogenomics plays an important role by identifying genetic factors that influence how individuals respond to medications to optimize treatment and avoid adverse reactions. Emerging areas of personalized medicine include 3D printing of customized drug delivery systems, remote pharmacy services through telepharmacy, and bioelectronic medicines that use electrical stimulation to treat diseases.
Applications of genomics and proteomics ppt
Applications of genomics and proteomics ppt
genomics and proteomics ppt
in the field of health genomics and proteomics ppt
oncology ppt
biomedical application of genomics and proteomics ppt
agriculture application of genomics and proteomics ppt
proteomics in agriculture ppt
diagnosis of infectious disease ppt
personalized medicine ppt
Application of genomic in Pharmacogenomicsof new drug
The document discusses the role of genomics in pharmacogenomics and drug development. It defines key terms like pharmacogenomics and pharmacogenetics. It explains how genomics technologies can help optimize drug efficacy and minimize toxicity by identifying genetic variations that influence individual drug responses. Genomic information from the human genome project can aid drug target identification and reduce bottlenecks in development. Single nucleotide polymorphisms are discussed as the most common genetic variations affecting drug metabolism. The applications of pharmacogenomics in precision medicine to improve drug safety and efficacy are summarized.
2034 5713-1-pb
1) The document discusses precision medicine in cancer treatment, which is a medical model that takes into account individual variability in genes, lifestyle, and environment to tailor treatment for each patient.
2) Precision medicine aims to improve cancer treatment outcomes by using biomarkers and genetic/molecular analysis to identify the specific causes of a patient's cancer and select targeted therapies.
3) This approach could help increase survival rates, reduce side effects, and improve overall treatment efficacy compared to traditional one-size-fits-all cancer care.
Advancements in Targeted Therapies for Precision Treatment
The field of precision medicine has witnessed remarkable progress in recent years, driven in large part by advancements in targeted therapies. These therapies, designed to address specific molecular or genetic characteristics of diseases, represent a paradigm shift in the way we approach medical treatment. This article explores the significant advancements in targeted therapies and their pivotal role in achieving precision treatment for various health conditions.
Cancer biomarker
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Cancer biomarker
introduction
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Personalized Therapies for OA: Can Biomarkers Get Us There?
This document discusses the potential for using biomarkers to enable personalized therapies for osteoarthritis (OA). It defines key terms like personalized therapies, biomarkers, phenotypes, and endotypes. The presenter argues that biomarkers could help identify the right treatment for individual OA patients by enabling prognostic and predictive enrichment in clinical trials. However, moving biomarkers from discovery to clinical validation and use involves a long process including assay development, testing biological links and hypotheses, and conducting randomized controlled trials. Several studies are highlighted that have discovered potential new biomarkers and are beginning to test biological links and hypotheses regarding how biomarkers may reflect disease processes and response to treatments.
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...The Lifesciences Magazine
Bone cancer prognosis provides valuable insights into the likelihood of recovery, recurrence, and overall survival rates for patients.ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...
ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...Prof. Eric Raymond Oncologie Medicale
Presented at the American Society for Clinical Oncology Gastroenterology in January 2017 in San Francisco by Eric Raymond
Background: Sunitinib was approved by the FDA in 2011 for treatment of progressive, well-differentiated, advanced pancreatic neuroendocrine tumors (pNETs) based on a pivotal phase III study (NCT00428597) that showed a significant increase in progression-free survival (PFS) over placebo following early study termination. Subsequently, the FDA requested a post-approval study to support these findings.
Methods: In this open-label, phase IV clinical trial (NCT01525550), patients with progressive, well-differentiated, unresectable advanced/metastatic pNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to the phase III study. Primary endpoint was investigator-assessed PFS per RECIST 1.0. This study is ongoing.
Results: Sixty one treatment-naïve and 45 previously treated patients with progressive pNETs were treated with sunitinib: mean age, 54.6 years; males, 59.4%; white, 63.2%; ECOG PS 0, 65.1% or PS 1, 34.0%; and prior somatostatin analog, 48.1% (treatment-naïve, 39.3%; previously treated, 60.0%). At the data cutoff date, 82 (77%) patients discontinued treatment, mainly due to disease progression (46%). Median duration of treatment was ~11.9 months. Investigator-assessed median PFS (mPFS) was 13.2 months (95% CI, 10.9–16.7) in the overall population, with comparable mPFS in treatment-naïve and previously treated patients (13.2 vs 13.0 months). mPFS per independent radiologic review was 11.1 months (95% CI, 7.4–16.6). Objective response rate (ORR) per RECIST was 24.5%: 21.3% in treatment-naïve and 28.9% in previously treated patients. Median overall survival, although not yet mature, was 37.8 months. Treatment-emergent, all-causality adverse events (AEs) reported by ≥20% of all patients included neutropenia, diarrhea, leukopenia, fatigue, hand–foot syndrome, hypertension, abdominal pain, dysgeusia, and nausea. Most common grade 3/4 AEs were neutropenia (22%) and diarrhea (9%).
Conclusions: The mPFS of 13.2 months and ORR of 24.5% observed in this study support the outcomes of the pivotal phase III study of sunitinib in pNETs and confirm its activity in this setting. AEs were consistent with known safety profile of sunitinib. More Related Content
Similar to prognostic marker for targeted therapy.pptx
Advances in Biomarkers and Personalized Medicine
Personalized medicine, also known as precision medicine, is an innovative approach to healthcare that takes into account individual variability in genes, environment, and lifestyle for each person. The goal of personalized medicine is to tailor medical decisions and treatments to the specific characteristics of each patient, maximizing therapeutic benefits while minimizing adverse effects. Biomarkers play a crucial role in achieving this personalized approach. Heres the background and significance of biomarkers in personalized medicine Biomarkers are measurable indicators that can be used to evaluate physiological, pathological, or pharmacological responses to disease or treatment. These can be genetic, molecular, biochemical, or imaging based markers that provide information about a patients health status, disease progression, or treatment response. The emergence of sophisticated biotechnological tools, such as genomics, proteomics, metabolomics, and imaging technologies, has revolutionized the field of medicine. These advancements enable the identification and analysis of biomarkers with greater precision and efficiency. K. Pavani | Jakkula Malavikabindu | Dayyala Naveen "Advances in Biomarkers and Personalized Medicine" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59709.pdf Paper Url:https://www.ijtsrd.com/medicine/other/59709/advances-in-biomarkers-and-personalized-medicine/k-pavani
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...The Lifesciences Magazine
Personalized medicine is a paradigm-shifting strategy that aims to give customized therapies based on individual features, genetic makeup, and distinct illness profiles in an era characterized by revolutionary developments in healthcare. DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
This document provides an overview of personalized medicines and various approaches related to personalized drug delivery. It discusses several key points:
1) Personalized medicine aims to integrate a patient's genetic information to select the most appropriate preventative measures or therapies tailored to that individual.
2) New technologies like custom drug delivery systems, 3D printing, and telepharmacy can help develop personalized treatments by optimizing drug efficacy and minimizing side effects.
3) Pharmacogenomics plays an important role in personalized medicine by using genetic data to inform drug development and identify responders, non-responders, and optimal dosages for individuals.
All About Oncology --- Plunes HealthCare
Oncologists work on identifying and minimizing risk factors associated with cancer. This can involve lifestyle changes, vaccinations (such as the HPV vaccine to prevent cervical cancer), and genetic counselling for individuals with a family history of certain cancers.
Precision Medicine in Oncology
Please share this webinar with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
Cancer care is increasingly tailored to individual patients, who can undergo genetic or biomarker testing soon after diagnosis, to determine which treatments have the best chance of shrinking or eliminating tumours.
In this webinar, a pathologist and clinical oncologist discuss:
● how they are using these new tests,
● how they communicate results and treatment options to patients and caregivers, and
● how patients can be better informed on the kinds of tests that are in development or in use across Canada
View the video: https://youtu.be/_Wai_uMQKEQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
med genetics
Medical genetics bridges medicine and biology by focusing on how genes influence health and disease. It has several key areas including clinical genetics, genetic counseling, cytogenetics, molecular genetics, and biochemical genetics. These areas involve diagnosing and managing genetic disorders, providing counseling and support to families, analyzing chromosomes, studying genes and mutations, and researching metabolic processes. Recent advances include gene therapy, personalized medicine, and genomics research, which aim to cure diseases, tailor treatments, and enhance understanding of gene-environment interactions, demonstrating medical genetics' potential to transform healthcare.
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptx
The document discusses personalized medicines and customized drug delivery systems. It defines personalized medicine as using genetic profiling and other individual patient characteristics to guide medical treatment. Customized drug delivery systems aim to optimize drug therapy for each patient by controlling dosage and delivery through technologies like bioelectronic medicines, 3D printing of pharmaceuticals, and telepharmacy.
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...PVI, PeerView Institute for Medical Education
Chair and Presenter, Sumanta Kumar Pal, MD, FASCO, Pedro C. Barata, MD, MSc, Toni K. Choueiri, MD, and Cristina Suarez, MD, PhD, prepared useful Practice Aids pertaining to renal cell carcinoma for this CME/MOC/NCPD/AAPA activity titled “Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the Disease Spectrum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at https://bit.ly/3yGnLnD. CME/MOC/NCPD/AAPA credit will be available until July 2, 2024.PERSONALIZED MEDICINE and customised drug delivery L-1.pptx
1. Personalized medicine aims to provide tailored treatment based on an individual's unique attributes by using diagnostic tools to identify biological markers, often genetic, to help assess which medical treatments will be most effective.
2. Pharmacogenomics plays a key role by studying how genetic variations affect individual responses to drugs to optimize efficacy and minimize adverse reactions. This allows for more targeted therapies and precise dosing.
3. The Human Genome Project mapped the entire human genetic code, opening up possibilities for diagnosing and treating diseases based on a person's genetic profile. Now, molecular testing guides treatment decisions and replaces some invasive procedures.
Personalized medicine, Pharmacogenomics, customized drug delivery systems,3d ...
Personalized medicine aims to improve health care by integrating information about a person's genes, proteins, and other factors to tailor medical treatment. This includes using genetic or other tests to select treatments, determine dosage, and predict drug responses. Pharmacogenomics plays an important role by identifying genetic factors that influence how individuals respond to medications to optimize treatment and avoid adverse reactions. Emerging areas of personalized medicine include 3D printing of customized drug delivery systems, remote pharmacy services through telepharmacy, and bioelectronic medicines that use electrical stimulation to treat diseases.
Applications of genomics and proteomics ppt
Applications of genomics and proteomics ppt
genomics and proteomics ppt
in the field of health genomics and proteomics ppt
oncology ppt
biomedical application of genomics and proteomics ppt
agriculture application of genomics and proteomics ppt
proteomics in agriculture ppt
diagnosis of infectious disease ppt
personalized medicine ppt
Application of genomic in Pharmacogenomicsof new drug
The document discusses the role of genomics in pharmacogenomics and drug development. It defines key terms like pharmacogenomics and pharmacogenetics. It explains how genomics technologies can help optimize drug efficacy and minimize toxicity by identifying genetic variations that influence individual drug responses. Genomic information from the human genome project can aid drug target identification and reduce bottlenecks in development. Single nucleotide polymorphisms are discussed as the most common genetic variations affecting drug metabolism. The applications of pharmacogenomics in precision medicine to improve drug safety and efficacy are summarized.
2034 5713-1-pb
1) The document discusses precision medicine in cancer treatment, which is a medical model that takes into account individual variability in genes, lifestyle, and environment to tailor treatment for each patient.
2) Precision medicine aims to improve cancer treatment outcomes by using biomarkers and genetic/molecular analysis to identify the specific causes of a patient's cancer and select targeted therapies.
3) This approach could help increase survival rates, reduce side effects, and improve overall treatment efficacy compared to traditional one-size-fits-all cancer care.
Advancements in Targeted Therapies for Precision Treatment
The field of precision medicine has witnessed remarkable progress in recent years, driven in large part by advancements in targeted therapies. These therapies, designed to address specific molecular or genetic characteristics of diseases, represent a paradigm shift in the way we approach medical treatment. This article explores the significant advancements in targeted therapies and their pivotal role in achieving precision treatment for various health conditions.
Cancer biomarker
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Cancer biomarker
introduction
What is biomarker?
What is the purpose of biomarker
Processes of biomarker development?
Types of Biomarkers
What is biomarker testing for cancer treatment?
Uses of Biomarkers in Cancer Medicine
Uses of Biomarkers in Cancer Drug Discovery
Personalized Therapies for OA: Can Biomarkers Get Us There?
This document discusses the potential for using biomarkers to enable personalized therapies for osteoarthritis (OA). It defines key terms like personalized therapies, biomarkers, phenotypes, and endotypes. The presenter argues that biomarkers could help identify the right treatment for individual OA patients by enabling prognostic and predictive enrichment in clinical trials. However, moving biomarkers from discovery to clinical validation and use involves a long process including assay development, testing biological links and hypotheses, and conducting randomized controlled trials. Several studies are highlighted that have discovered potential new biomarkers and are beginning to test biological links and hypotheses regarding how biomarkers may reflect disease processes and response to treatments.
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...The Lifesciences Magazine
Bone cancer prognosis provides valuable insights into the likelihood of recovery, recurrence, and overall survival rates for patients.ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...
ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...Prof. Eric Raymond Oncologie Medicale
Presented at the American Society for Clinical Oncology Gastroenterology in January 2017 in San Francisco by Eric Raymond
Background: Sunitinib was approved by the FDA in 2011 for treatment of progressive, well-differentiated, advanced pancreatic neuroendocrine tumors (pNETs) based on a pivotal phase III study (NCT00428597) that showed a significant increase in progression-free survival (PFS) over placebo following early study termination. Subsequently, the FDA requested a post-approval study to support these findings.
Methods: In this open-label, phase IV clinical trial (NCT01525550), patients with progressive, well-differentiated, unresectable advanced/metastatic pNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to the phase III study. Primary endpoint was investigator-assessed PFS per RECIST 1.0. This study is ongoing.
Results: Sixty one treatment-naïve and 45 previously treated patients with progressive pNETs were treated with sunitinib: mean age, 54.6 years; males, 59.4%; white, 63.2%; ECOG PS 0, 65.1% or PS 1, 34.0%; and prior somatostatin analog, 48.1% (treatment-naïve, 39.3%; previously treated, 60.0%). At the data cutoff date, 82 (77%) patients discontinued treatment, mainly due to disease progression (46%). Median duration of treatment was ~11.9 months. Investigator-assessed median PFS (mPFS) was 13.2 months (95% CI, 10.9–16.7) in the overall population, with comparable mPFS in treatment-naïve and previously treated patients (13.2 vs 13.0 months). mPFS per independent radiologic review was 11.1 months (95% CI, 7.4–16.6). Objective response rate (ORR) per RECIST was 24.5%: 21.3% in treatment-naïve and 28.9% in previously treated patients. Median overall survival, although not yet mature, was 37.8 months. Treatment-emergent, all-causality adverse events (AEs) reported by ≥20% of all patients included neutropenia, diarrhea, leukopenia, fatigue, hand–foot syndrome, hypertension, abdominal pain, dysgeusia, and nausea. Most common grade 3/4 AEs were neutropenia (22%) and diarrhea (9%).
Conclusions: The mPFS of 13.2 months and ORR of 24.5% observed in this study support the outcomes of the pivotal phase III study of sunitinib in pNETs and confirm its activity in this setting. AEs were consistent with known safety profile of sunitinib. Similar to prognostic marker for targeted therapy.pptx (20)
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...
Personalized Medicine: Foundation, Applications, Challenges and Opportunities...
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DOSAGE FORMS OF PERSONALISED MEDICINES BY SUBHAM - Copy.pptx
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptx
DDS personalised medicines M.Pharma 1st Sem Pharmaceutics.pptx
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
Fine-Tuning the Wave of Innovation in RCC: Personalized Management Across the...
PERSONALIZED MEDICINE and customised drug delivery L-1.pptx
PERSONALIZED MEDICINE and customised drug delivery L-1.pptx
Personalized medicine, Pharmacogenomics, customized drug delivery systems,3d ...
Personalized medicine, Pharmacogenomics, customized drug delivery systems,3d ...
Application of genomic in Pharmacogenomicsof new drug
Application of genomic in Pharmacogenomicsof new drug
Advancements in Targeted Therapies for Precision Treatment
Advancements in Targeted Therapies for Precision Treatment
Personalized Therapies for OA: Can Biomarkers Get Us There?
Personalized Therapies for OA: Can Biomarkers Get Us There?
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...
What is Bone Cancer Prognosis? Treatment and Influencing Factors | The Lifesc...
ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...
ASCO-GI: The efficacy and safety of sunitinib in patients with advanced well-...
Recently uploaded
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
All info about Diabetes and how to control it.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
Top Travel Vaccinations in Manchester
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
Role of Mukta Pishti in the Management of Hyperthyroidism
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Identifying Major Symptoms of Slip Disc.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Recently uploaded (20)
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptx
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Role of Mukta Pishti in the Management of Hyperthyroidism
Role of Mukta Pishti in the Management of Hyperthyroidism
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
prognostic marker for targeted therapy.pptx
- 1. Prognostic markers for targeted therapy Dr.Atul GMCH THE NILGIRIS
- 2. What is targeted therapy? ✔Targeted therapy is a type of cancer treatment. ✔That control proteins that control targets how cancer cell grow, divide and spread. ✔It is the foundation of precision medicine. ✔Targeted therapy provides specific treatment against a specific type of cancer.
- 3. What is prognostic markers? ● Prognostic markers are biological factors that can be used to predict how likely a patient is to respond to a particular treatment. ● Prognostic markers can be used to select the best treatment For each patient.
- 4. Types of prognostic markers? Mainly 2 types. 1. Clinical prognostic markers 2. Biological prognostic markers
- 5. 1. Clinical prognostic markers ● patients age ● stage of cancer ● overall health status.
- 6. 2. Biological prognostic markers Factors can be measured in- ● Patients blood ● Tumor tissue, such as expression of certain genes or protiens.
- 7. How prognostic markers used in targeted therapy? • To select patients who are most likely to benefit from a particular treatment. • To monitor the response to treatment and identify patients who may need to switch to a different treatment. • To predict the risk of recurrence or progression of cancer.
- 8. Examples of prognostic markers in targeted therapy? ● BRAF – mutation status in melanoma ● EGFR – mutation status in lung cancer ● HER2 – overexpression in breast cancer ● ALK – rearrangement in non-small cell lung cancer
- 9. Thank you